Loading…
Collegium Pharmaceutical, Inc. is projected to rise to $36.58 by 2027, a +9% move from its current price of $33.68. COLL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $33.03 | $33.70 | $34.39 | +0.06% |
| May 30 | $32.77 | $33.72 | $34.69 | +0.11% |
| May 31 | $32.58 | $33.74 | $34.94 | +0.17% |
| Jun 1 | $32.42 | $33.76 | $35.15 | +0.23% |
| Jun 2 | $32.28 | $33.78 | $35.33 | +0.28% |
| Jun 3 | $32.16 | $33.79 | $35.51 | +0.34% |
| Jun 4 | $32.05 | $33.81 | $35.67 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.05 | $33.81 | $35.67 | +0.40% |
| Week 2 | $31.48 | $33.95 | $36.61 | +0.79% |
| Week 3 | $31.07 | $34.08 | $37.39 | +1.19% |
| Week 4 | $30.75 | $34.22 | $38.07 | +1.60% |
| Week 5 | $30.49 | $34.35 | $38.71 | +2.00% |
| Week 6 | $30.26 | $34.49 | $39.31 | +2.40% |
| Week 7 | $30.06 | $34.63 | $39.88 | +2.81% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Collegium Pharmaceutical, Inc. is a healthcare company that operates as a specialty pharmaceutical company focused on the development and commercialization of medicines for pain management. The portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. is a healthcare stock. The current price is $34.07 and the market cap is $1.11B, with a rank of 2464. The stock’s forecast horizon extends to 2050, and the outlook indicates a transition from neutral to bullish over time as averages rise.
A major floor 16.7% below — a decisive break under it would weaken the trend.
The nearest floor, 4.2% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 43.1% above — clearing it would confirm fresh momentum.
Key COLL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of COLL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.03 | Sell | $33.94 | Sell |
| MA 10 | $34.09 | Sell | $34.22 | Sell |
| MA 20 | $34.89 | Sell | $34.45 | Sell |
| MA 50 | $34.24 | Sell | $35.47 | Sell |
| MA 100 | $39.20 | Sell | $37.30 | Sell |
| MA 200 | $39.70 | Sell | $37.71 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.08 | Neutral |
| Stoch RSI (14) | 2.18 | Buy |
| CCI (20) | -72.39 | Neutral |
| Williams %R (14) | -98.95 | Info |
| MACD (12,26,9) | -0.15 | Sell |
| ROC (12) | -10.90 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 1.05 | Buy |
| TRIX (15) | -0.00 | Sell |
| Awesome (5,34) | -0.47 | Sell |
| Ultimate (7,14,28) | 44.56 | Neutral |
| Momentum (10) | -2.01 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 33.94 | Sell |
| ADX (14) | 13.53 | Neutral |
| ATR (14) | 0.58 | Info |
The 30-day technical picture is bearish, with the RSI14 at 50. The 50-day moving average sits at $34.29 and the 200-day moving average at $39.70. Near-term support is at $32.28 and resistance at $39.33. The stock has traded within a 30-day range of $29.59 to $39.23 and shows an annualized volatility of 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $31.99 | $33.68 | $42.02 | 0% | Neutral | |
| $29.75 | $36.58 | $47.19 | +9% | Neutral | |
| $29.72 | $37.27 | $49.42 | +11% | Neutral | |
| $30.93 | $39.42 | $53.43 | +17% | Neutral | |
| $34.12 | $44.11 | $60.89 | +31% | Bullish | |
| $38.15 | $49.96 | $70.11 | +48% | Bullish | |
| $41.91 | $55.56 | $79.13 | +65% | Bullish | |
| $42.67 | $57.21 | $82.58 | +70% | Bullish | |
| $42.67 | $57.81 | $84.50 | +72% | Bullish | |
| $43.42 | $59.44 | $87.89 | +76% | Bullish | |
| $63.56 | $91.05 | $141.41 | +170% | Bullish | |
| $97.03 | $150.03 | $250.58 | +345% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $31.99 | $33.68 | $39.49 | +0.00% |
| June 2026 | $29.78 | $34.78 | $41.43 | +3.27% |
| July 2026 | $30.18 | $35.46 | $42.67 | +1.95% |
| August 2026 | $29.63 | $34.99 | $42.43 | -1.34% |
| September 2026 | $29.52 | $34.99 | $42.70 | +0.02% |
| October 2026 | $29.83 | $35.49 | $43.56 | +1.43% |
| November 2026 | $29.23 | $34.89 | $43.04 | -1.69% |
| December 2026 | $28.31 | $33.90 | $42.02 | -2.84% |
Click any year to see its month-by-month COLL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect COLL to range from $31.99 to $42.02 through 2026. The $33.68 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The COLL price prediction for 2027 points to an average of $36.58 (low $29.75, high $47.19) — a potential gain of +9% on today's $33.68. Price action looks broadly range-bound.
In 2028, COLL is projected to trade between $29.72 and $49.42, averaging $37.27 — a potential gain of +11% from today's $33.68. That is up +2% on the projected 2027 average. A consolidation phase looks the most probable path here.
Collegium Pharmaceutical, Inc.'s 2029 outlook centres on $39.42, within a $30.93 to $53.43 range. That is up +6% on the projected 2028 average. That marks a +17% change versus current levels. Price action looks broadly range-bound.
By 2030, COLL could reach as high as $60.89, with a base case around $44.11 and support toward $34.12 — roughly +31% from $33.68. Buyers look set to stay in control over this stretch.
Expect COLL to range from $38.15 to $70.11 through 2031. The $49.96 average target implies a +48% move from current prices. That is up +13% on the projected 2030 average. Momentum favours further upside here.
The COLL price prediction for 2032 points to an average of $55.56 (low $41.91, high $79.13) — a potential gain of +65% on today's $33.68. Buyers look set to stay in control over this stretch.
In 2033, COLL is projected to trade between $42.67 and $82.58, averaging $57.21 — a potential gain of +70% from today's $33.68. That is up +3% on the projected 2032 average. Momentum favours further upside here.
Collegium Pharmaceutical, Inc.'s 2034 outlook centres on $57.81, within a $42.67 to $84.50 range. That is up +1% on the projected 2033 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, COLL could reach as high as $87.89, with a base case around $59.44 and support toward $43.42 — roughly +76% from $33.68. Momentum favours further upside here.
Expect COLL to range from $63.56 to $141.41 through 2040. The $91.05 average target implies a +170% move from current prices. That is up +53% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The COLL price prediction for 2050 points to an average of $150.03 (low $97.03, high $250.58) — a potential gain of +345% on today's $33.68. Momentum favours further upside here.
Investing $1,000 in COLL today (≈ 29.691211 COLL) could be worth
$4,454.45
+$3,454.45 (+345%) by 2050 · US Dollar
Based on the average projected COLL price of $150.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in COLLwould be worth at today's price.
$1,000 invested in COLL on May 27, 2025 (≈ 33.921303 COLL) would be worth
$1,142.47
+$142.47 (+14.2%) today · 1.14× · US Dollar
Based on a COLL entry price of $29.48 vs. today's $33.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.22 | $984.22 | -1.6% |
| 1 month ago | $32.78 | $1,027.46 | +2.7% |
| 3 months ago | $44.22 | $761.65 | -23.8% |
| 6 months ago | $46.68 | $721.51 | -27.8% |
| 1 year ago | $29.48 | $1,142.47 | +14.2% |
| All time (5.0y) ago | $22.9 | $1,470.74 | +47.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our COLL forecast.
Our base-case forecast reaches $67.00 around 2040.
Implied market cap at $67.00: $2.17B
The multi-year forecast shows a clear upcycle beginning in 2030. For 2026 the min is $31.99, the avg is $34.07 and the max is $42.66, with an ROI of 0 and sentiment NEUTRAL. In 2027 the avg rises to $37.26 (ROI 9.3), and in 2028 to $37.69 (ROI 10.6).
By 2029 the avg is $39.95 (ROI 17.3). In 2030 the avg becomes $45.03 (ROI 32.2) with a max of $62.78 and bullish sentiment. The sequence continues through 2031 ($50.64 avg, ROI 48.6), 2032 ($56.51 avg, ROI 65.9), 2033 ($58.31 avg, ROI 71.1), 2034 ($58.39 avg, ROI 71.4), and 2035 ($60.57 avg, ROI 77.8), all bullish.
By 2040 the avg is $92.33 (ROI 171) with a max of $145.61, and by 2050 the avg reaches $153.09 (ROI 349.3) with a max of $260.42. These figures imply a long-run bullish trajectory, though they are estimates and not guaranteed.
Tap a question to reveal the answer.
2030 forecast shows min $34.56, avg $45.03, max $62.78 with ROI 32.2 and sentiment BULLISH.
The forecast shows a path from neutral in 2026–2029 to bullish from 2030 onward, with notable upside by 2040 ($92.33 avg; ROI 171) and by 2050 ($153.09 avg; ROI 349.3). Near-term numbers include 2027 avg $37.26 (ROI 9.3) and 2028 avg $37.69 (ROI 10.6).
Yes. The 2030 max forecast is $62.78, which exceeds $60.
For 2026, min $31.99, avg $34.07, max $42.66; sentiment NEUTRAL.
Current price is $34.07 and market cap is $1.11B.
Collegium Pharmaceutical, Inc. Community Discussion
0Share your Collegium Pharmaceutical, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.